Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?

被引：132
作者：
Khan, RB
Shi, WJ
Thaler, HT
DeAngelis, LM
Abrey, LE
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
来源：
JOURNAL OF NEURO-ONCOLOGY | 2002年 / 58卷 / 02期
关键词：
primary CNS lymphoma; intrathecal chemotherapy; methotrexate; neurotoxicity;
D O I：
10.1023/A:1016077907952
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Systemic high-dose methotrexate (HD-MTX) is the most effective chemotherapeutic agent in the treatment of primary central nervous system lymphoma (PCNSL). Leptomeningeal involvement is common and intrathecal methotrexate (IT-MTX) is frequently used in combination with HD-MTX, but its benefits are not established. Using a case-controlled retrospective study, matching patients treated with HD-MTX with or without IT-MTX, we found no difference in survival, disease control, or neurotoxicity.
引用
收藏
页码：175 / 178
页数：4
相关论文
共 11 条
[1]   Treatment for primary CNS lymphoma: The next step [J].
Abrey, LE ;
Yahalom, J ;
DeAngelis, LM .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3144-3150
[2]   LEPTOMENINGEAL TUMOR IN PRIMARY CENTRAL-NERVOUS-SYSTEM LYMPHOMA - RECOGNITION, SIGNIFICANCE, AND IMPLICATIONS [J].
BALMACEDA, C ;
GAYNOR, JJ ;
SUN, M ;
GLUCK, JT ;
DEANGELIS, LM .
ANNALS OF NEUROLOGY, 1995, 38 (02) :202-209
[3]   Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases [J].
Chamberlain, MC ;
Kormanik, PA ;
Barba, D .
JOURNAL OF NEUROSURGERY, 1997, 87 (05) :694-699
[4]   METHOTREXATE CEREBROSPINAL-FLUID AND SERUM CONCENTRATIONS AFTER INTERMEDIATE-DOSE METHOTREXATE INFUSION [J].
EVANS, WE ;
HUTSON, PR ;
STEWART, CF ;
CAIRNES, DA ;
BOWMAN, WP ;
RIVERA, G ;
CROM, WR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 33 (03) :301-307
[5]   RANDOMIZED PROSPECTIVE COMPARISON OF INTRAVENTRICULAR METHOTREXATE AND THIOTEPA IN PATIENTS WITH PREVIOUSLY UNTREATED NEOPLASTIC MENINGITIS [J].
GROSSMAN, SA ;
FINKELSTEIN, DM ;
RUCKDESCHEL, JC ;
TRUMP, DL ;
MOYNIHAN, T ;
ETTINGER, DS .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :561-569
[6]   Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: Response to therapy and quality of life of patients [J].
Guha-Thakurta, N ;
Damek, D ;
Pollack, C ;
Hochberg, FH .
JOURNAL OF NEURO-ONCOLOGY, 1999, 43 (03) :259-268
[7]   Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas [J].
Hiraga, S ;
Arita, N ;
Ohnishi, T ;
Kohmura, E ;
Yamamoto, K ;
Oku, Y ;
Taki, T ;
Sato, M ;
Aozasa, K ;
Yoshimine, T .
JOURNAL OF NEUROSURGERY, 1999, 91 (02) :221-230
[8]   Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: An association with intermediate-dose intravenous methotrexate and intrathecal triple therapy - A Pediatric Oncology Group study [J].
Mahoney, DH ;
Shuster, JJ ;
Nitschke, R ;
Lauer, SJ ;
Steuber, CP ;
Winick, N ;
Camitta, B .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) :1712-1722
[9]   Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma [J].
McAllister, LD ;
Doolittle, ND ;
Guastadisegni, PE ;
Kraemer, DF ;
Lacy, CA ;
Crossen, JR ;
Neuwelt, EA .
NEUROSURGERY, 2000, 46 (01) :51-60
[10]   CENTRAL NERVOUS-SYSTEM METASTASES FROM NON-HODGKINS LYMPHOMA - TREATMENT AND PROPHYLAXIS [J].
RECHT, L ;
STRAUS, DJ ;
CIRRINCIONE, C ;
THALER, HT ;
POSNER, JB .
AMERICAN JOURNAL OF MEDICINE, 1988, 84 (03) :425-435
12